{"id":"emend-aprepitant","safety":{"commonSideEffects":[{"rate":"18","effect":"Fatigue"},{"rate":"9","effect":"Constipation"},{"rate":"8","effect":"Diarrhea"},{"rate":"7","effect":"Headache"},{"rate":"5","effect":"Hiccups"}]},"_chembl":{"chemblId":"CHEMBL4303169","moleculeType":"Small molecule","molecularWeight":"534.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aprepitant is a selective antagonist of human neurokinin-1 (NK1) receptors, which are involved in the emetic reflex. By crossing the blood-brain barrier and binding to NK1 receptors in the chemoreceptor trigger zone and vomiting center, it prevents the transmission of signals that trigger nausea and vomiting, particularly those induced by highly emetogenic chemotherapy agents.","oneSentence":"Aprepitant blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:42.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy"},{"name":"Prevention of postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT06931119","phase":"PHASE1","title":"Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Rabin Medical Center","startDate":"2025-05-30","conditions":"Pruritus","enrollment":30},{"nctId":"NCT04054193","phase":"PHASE4","title":"Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-09","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":103},{"nctId":"NCT06427681","phase":"EARLY_PHASE1","title":"An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Zhuhai Beihai Biotech Co., Ltd","startDate":"2024-05","conditions":"Bioavailability","enrollment":40},{"nctId":"NCT01504711","phase":"NA","title":"Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy","status":"COMPLETED","sponsor":"Philip Philip","startDate":"2012-06","conditions":"Gastrointestinal Cancer, Nausea Post Chemotherapy","enrollment":30},{"nctId":"NCT01661335","phase":"PHASE3","title":"Efficacy of Aprepitant (Emend®) in Children","status":"COMPLETED","sponsor":"University of Oklahoma","startDate":"2012-06-01","conditions":"Nausea, Vomiting, Childhood Cancer","enrollment":19},{"nctId":"NCT04075955","phase":"PHASE3","title":"Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapy","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2019-04-29","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":30},{"nctId":"NCT01176591","phase":"PHASE2","title":"HBPL Study of the Impact of the NK1 Antagonist Aprepitant","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-09","conditions":"Cocaine Dependence, Alcohol Dependence","enrollment":13},{"nctId":"NCT03889366","phase":"PHASE1","title":"Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers","status":"COMPLETED","sponsor":"Nuformix Technologies Limited","startDate":"2019-03-20","conditions":"Healthy","enrollment":12},{"nctId":"NCT01697579","phase":"PHASE2","title":"Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-13","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":240},{"nctId":"NCT02519842","phase":"PHASE3","title":"Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-14","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":75},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":"Oncology","enrollment":426},{"nctId":"NCT01362530","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-13","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":307},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":"Nausea, Vomiting","enrollment":494},{"nctId":"NCT01405924","phase":"PHASE2","title":"Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-25","conditions":"Nausea, Vomiting","enrollment":111},{"nctId":"NCT02154360","phase":"PHASE1","title":"Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-05","conditions":"HIV Infection","enrollment":12},{"nctId":"NCT00381862","phase":"PHASE2","title":"Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-06","conditions":"Colorectal Cancer, Nausea and Vomiting","enrollment":54},{"nctId":"NCT00337727","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":848},{"nctId":"NCT00428519","phase":"PHASE1","title":"Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2007-01","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT01300988","phase":"PHASE1","title":"Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-12","conditions":"HIV Infection","enrollment":18},{"nctId":"NCT00293384","phase":"NA","title":"Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2004-10","conditions":"Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor","enrollment":40},{"nctId":"NCT01101529","phase":"PHASE2","title":"Treatment of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Uppsala University Hospital","startDate":"2010-05","conditions":"Nausea, Vomiting","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Emend®"],"phase":"phase_3","status":"active","brandName":"Emend® (Aprepitant)","genericName":"Emend® (Aprepitant)","companyName":"CR-CSSS Champlain-Charles-Le Moyne","companyId":"cr-csss-champlain-charles-le-moyne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aprepitant blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy, Prevention of postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}